Makorin-2 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Makorin-2 protein, a member of the zinc finger protein family. Makorin-2 (MKRN2) is known for its role in various cellular processes, including the regulation of RNA metabolism and ubiquitin-mediated protein degradation. It contains multiple zinc finger domains, which allow it to interact with nucleic acids and other proteins, facilitating its function as an E3 ubiquitin ligase. This function is essential in marking certain proteins for degradation by the proteasome, thereby maintaining cellular protein homeostasis. By inhibiting MKRN2, these inhibitors can alter the regulation of these processes, which in turn may influence the stability of key cellular proteins involved in transcription, signaling, and various regulatory mechanisms.
Chemically, Makorin-2 inhibitors are typically characterized by their ability to bind to the zinc finger motifs or to other critical domains necessary for MKRN2's ligase activity. These inhibitors may interact with the active site of MKRN2 or induce conformational changes that reduce its ability to catalyze ubiquitination. Structurally, these compounds often contain reactive groups that form stable interactions with the key residues involved in MKRN2's catalytic function. The study of these inhibitors involves detailed analysis of their binding affinities, structural configurations, and the specific mechanisms through which they disrupt MKRN2's role in ubiquitination pathways. Further exploration into this class of inhibitors has provided insights into their potential to modulate diverse cellular pathways, given the wide-ranging effects of ubiquitin-protein interactions on intracellular signaling and gene expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 might inhibit MKRN2 by blocking the proteasome pathway, which is crucial for protein degradation processes where MKRN2 is involved. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine could affect the lysosomal degradation pathway, indirectly impacting the ubiquitination process where MKRN2 participates. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
This compound could inhibit autophagy, indirectly affecting the cellular processes where MKRN2 is involved. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib might inhibit the proteasome pathway, affecting the protein degradation where MKRN2 has a role. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
By stabilizing p53, Nutlin-3 could influence the expression of genes involved in the ubiquitin-proteasome pathway, including MKRN2. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
This compound could inhibit the endoplasmic reticulum-associated degradation, affecting MKRN2 function indirectly. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib (MLN2238) might impact the ubiquitination process by inhibiting proteasome activity, affecting MKRN2 function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
This compound might inhibit proteasome activity, affecting the ubiquitination processes where MKRN2 is involved. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
PR-619 might inhibit ubiquitin-specific proteases, influencing the ubiquitination process where MKRN2 participates. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib could inhibit the proteasome pathway, affecting the protein degradation processes where MKRN2 is involved. | ||||||